Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467250 | 0.72 | SNCA (0.50) | LMNAHPGDGFERHSD17B10TRPA1 | |
| SCHEMBL28470729 | 0.72 | SNCA (0.50) | LMNAHPGDGFERHSD17B10TRPA1 | |
| SCHEMBL15586614 | 0.72 | EPHX2 (0.63) | LMNAHPGDGFERHSD17B10ALDH1A1 | |
| SCHEMBL8349080 | 0.69 | OGA (0.39) | LMNAHPGDGFERHSD17B10TRPA1 | |
| SCHEMBL15341645 | 0.69 | GAA (0.44) | LMNAHPGDGFERHSD17B10TRPA1 | |
| SCHEMBL24371401 | 0.69 | LMNA (0.39) | LMNAHPGDGFERHSD17B10TRPA1 | |
| SCHEMBL8863082 | 0.69 | MAOA (0.52) | LMNAHPGDHSD17B10GAAALDH1A1 | |
| SCHEMBL8472050 | 0.69 | SNCA (0.38) | GAAALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL8471378 | 0.69 | AHR (0.37) | GAAMEN1MAPTKMT2AHTR1D | |
| SCHEMBL8863075 | 0.69 | KIF11 (0.37) | LMNAHPGDHSD17B10GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-2802576-B1 | HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-27 | — | — | EP | disclosed |
| US-9957275-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2016-09-08 | — | — | US | disclosed |
| US-8133513-B2 | Solid preparation having improved solubility | SHIONOGI & CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133513-B2 | Solid preparation having improved solubility | SHIONOGI & CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090105312-A1 | SOLID PREPARATION HAVING IMPROVED SOLUBILITY | SHIONOGI & CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105312-A1 | SOLID PREPARATION HAVING IMPROVED SOLUBILITY | SHIONOGI & CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | LMNA 3626/4885HPGD 1755/4885GFER 4522/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | LMNA 2696/4885HPGD 3623/4885GFER 3611/4885 |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | ACSS2, ACACB, ADCY2 | LMNA 4337/4885HPGD 3218/4885GFER 654/4885 |
| US-20090105312-A1 | SOLID PREPARATION HAVING IMPROVED SOLUBILITY | NUDT1, PDE7A, SLC7A1 | LMNA 1838/4885HPGD 75/4885GFER 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.